Loading
Azenta, Inc. Stock: price and insider trades · United States
1 insider bought €7,029 of shares over the last 90 days, the latest filed 04 Aug 2026.
Azenta, Inc.: what insiders have been doing
Headquartered in Burlington, United States, Azenta, Inc. belongs to the Healthcare & Pharma sector. Its latest reported headcount is 1,176 employees (2023). Filings by its managers are published through SEC (Form 4). In the past year (18 October 2025 to 18 October 2026), 25 filings came from 13 insiders.
Every open-market trade in the period is a purchase: 1 purchase worth €7,029, from 1 insider, and not a single sale. Open-market purchases are the filings investors watch most closely, because the insider pays for the shares out of pocket. On the buying side, the filings list 1 senior executive among the declarants. One trade stands out by size: a purchase of €7,029 from Starr Ephraim, disclosed on 4 August 2026, or 0.0005% of market capitalisation.
For context, the typical company on the same exchange (median of 5,458 companies) published 22 filings over the same period, against 25 filings here. Over the whole record (from 2016), the tally stands at 12 purchases and 38 sales. On the fundamentals side, the SEC filing (10-K) for the period ending 30 September 2025 lists revenue at 593.8 m USD and net income at -55.8 m USD.
The most recent open-market purchase was published on 4 August 2026, 75 days ago. The median gap between a trade and its publication by SEC (Form 4) is 2 days. For comparison, the SEC allows two business days to file a Form 4.
For comparison within the same sector, see the insider buying recorded at Anixa Biosciences Inc and Vivos Inc. This summary is built from SEC (Form 4) disclosures alone and does not predict where the share price will go.
Insider Decl.
215
Thresholds
n/a
Buy Volume
€2M
12 ops. · all time
Sell Volume
€18M
38 ops. · all time
Who traded when
BuySaleGinger Zhou1 buy1 sale
Violetta Hughes2 sales
David Dong Wang1 sale
Didier Hirsch1 buy
Ephraim Starr1 buy
Herman Cueto1 sale
+6 other insiders
Since the insiders bought
- +6.2%Entry US$31.82 · Close 16 Oct 2026 US$33.78
- +5.7%Entry US$32.08 · Close at T+365 US$33.91
- -48.2%Entry US$53.76 · Close at T+365 US$27.85
Entry is the close on the day after publication, the first price a reader could act on. Prices in the listing currency. Past moves are not a forecast.
Analyst consensus: bullish or bearish?
Analysts rate Azenta, Inc. Buy (bullish), based on 4 analysts. Average price target: US$39.00.
This score ranks the purchase within its own market. A position size is suggested only on the venues of the backtested strategy universe; elsewhere, signals stay on watch. Not investment advice.
Fundamental score
Ranked 18,436 of 24,158 companies
33.6
score / 100
Value27
Quality40
FCF yld2.6%
Earn yld-3.7%
EV/EBITDA39.1x
ROE-7.0%
Gross mgn46%
Net mgn-9.4%
Debt/EBITDA1.3x
Pillars2/3
Transparent value + quality ranking, distinct from the insider signal.
Financial data
as of FY 2025FY ended September 2025 · cache
US$34.09
Analyst consensus
4 analystsBuy
US$33.00Target US$39.00(+14%)US$44.00
Income statement
RevenueUS$593.8M
Gross profitUS$270.3M46% margin
EBITDAUS$39.5M7% margin
Net income-US$55.8M-20.0% margin
Valuation
PER (forward)61.7x
P/Book1.0x
Beta1.52
Balance sheet & cash
Market capUS$1.5B
Total debtUS$51.2M
Free Cash FlowUS$38.3M
Debt / Equity4%
Profitability & ownership
ROE-7.0%
ROA-0.7%
% insiders1.3%
% institutions117.8%
Last declaration on 23 September 2026
Declarations215 total
1,456 shares@ US$34.280.0033% mcap11.3% of flowCommonSEC:0001628280-26-063164:0
15,272 shares0CommonSEC:0001628280-26-062343:0
30,544 shares0CommonSEC:0001628280-26-062344:0
4,586 shares0CommonSEC:0001628280-26-062341:0
15,272 shares0CommonSEC:0001628280-26-062345:0
15,272 shares0CommonSEC:0001628280-26-062348:0
36,653 shares0CommonSEC:0001628280-26-062354:0
1,085 shares@ US$32.040.0023% mcap3.0% of flowCommonSEC:0001628280-26-055760:0
335 shares@ US$24.16760.0005% mcap0.8% of flowCommonSEC:0001628280-26-052799:0
Canonical exit: 29 Oct 2026 (T+90)
5,663 shares0Common StockSEC:0001104659-26-059359:0
17,790 shares@ US$24.240.028% mcap100.0% of flowCommonSEC:0001949513-26-000008:0
5,663 shares@ US$27.8527.4% of flowCommonSEC:0001193125-26-041476:0
5,663 shares@ US$27.8527.4% of flowCommonSEC:0001193125-26-041527:0
5,663 shares@ US$27.8539.6% of flowCommonSEC:0001193125-26-041482:0
7,243 shares@ US$27.8526.2% of flowCommonSEC:0001193125-26-041478:0
118,194 shares0CommonSEC:0001193125-25-307099:0
34,235 shares0CommonSEC:0001193125-25-297823:0
13,042 shares0CommonSEC:0001193125-25-297830:0
16,303 shares0CommonSEC:0001193125-25-297837:0
36,681 shares0CommonSEC:0001193125-25-297842:0
122,269 shares0CommonSEC:0001193125-25-297847:0
1,118 shares@ US$29.753.4% of flowCommonSEC:0001193125-25-284747:0
1,553 shares@ US$29.753.9% of flowCommonSEC:0001193125-25-284743:0
3,039 shares@ US$29.756.1% of flowCommonSEC:0001193125-25-284737:0
10,980 shares@ US$29.757.3% of flowCommonSEC:0001193125-25-284729:0
25 of 215 declarations
About Azenta, Inc.
Azenta, Inc. (Nasdaq: AZTA) is a United States-listed life sciences company traded on the NASDAQ market. For investors, Azenta sits at the intersection of biomedical research, laboratory automation, sample storage, and advanced data-enabled workflows. The company is headquartered in Burlington, Massachusetts, placing it in one of the most important U.S. biotechnology and life-sciences clusters.
Azenta was created through the restructuring and rebranding of the former Brooks Automation life sciences businesses. The company’s history reflects a deliberate strategic shift toward higher-value, more specialized offerings for research institutions, biobanks, contract research organizations, pharmaceutical companies, and biotechnology customers. Rather than operating as a broad industrial supplier, Azenta has built a focused life sciences platform designed to help customers store, manage, explore, and analyze biological samples more efficiently across the research and development pipeline.
Read moreShow less
Its main business lines typically include sample management and cold-chain storage systems, automated sample handling and laboratory robotics, biorepository services, software for sample tracking and inventory management, and multiomics or gene-synthesis related capabilities. This mix gives Azenta a differentiated position: it combines hardware, software, and services in a workflow-oriented model that can be embedded deeply into customer operations. That integrated approach is important in a market where accuracy, chain-of-custody, scalability, and reproducibility are critical.
From a competitive standpoint, Azenta is best viewed as a specialist rather than a diversified conglomerate. Its market position benefits from secular demand for automation, cryogenic preservation, digital sample management, and biologically relevant data generation. The company serves a global customer base, with operations, laboratories, biorepositories, and manufacturing capabilities across North America, Europe, and Asia. This international footprint supports revenue diversification and helps Azenta participate in research spending across multiple major life-sciences regions.
Recent developments have emphasized portfolio simplification and strategic focus. In late 2025, Azenta announced a definitive agreement to sell its B Medical Systems business, a move designed to concentrate capital and management attention on core capabilities with stronger strategic fit. The company also authorized a $250 million share repurchase program in December 2025, underscoring management’s commitment to capital return and shareholder value. In 2026, Azenta continued to advance its multiomics and gene-synthesis execution through leadership changes and strategic partnerships, including collaborations aimed at gene therapy development and space-based life-sciences research infrastructure. Overall, Azenta offers investors exposure to the Health & Pharma sector with a specialty profile, an innovation-driven growth runway, and a clearer focus on profitable core platforms.
Recent ranked signals in the same sector
Purchases our model currently ranks for the recommendations list.
All recommendations
